Neuroplast, a Dutch clinical-stage biotech, focusing on cell-based treatments for neurodegenerative diseases, has successfully completed patient inclusion of its Phase II randomized placebo-controlled double-blinded clinical trial to evaluate the effect size of Neuro-Cells® for Traumatic Spinal Cord Injury (TSCI) .
16 patients have been enrolled in a multicenter international, randomized, placebo-controlled, double-blinded Phase II clinical trial Goal: to determine the.
Neuro-Cells treatment aims to reduce irreversible damage to the central nervous system from secondary inflammation following traumaThe randomized, placebo-controlled, international multi-center